US4729993A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Carbapenems and 1-methylcarbapenems having an externally alkylated mono- or bicyclic 2-quaternary heteroarylalkyl substituent
Assignee: Merck and Co Inc
•
Filing: 1984-12-13
•
Granted: 1988-03-08
•
Expires: 2004-12-13
Abstract
Abstract Carbapenems having the formula: ##STR1## wherein ##STR2## is mono- or bicyclic quaternary heteroaryl, their preparation and antibiotic use are disclosed.
Inventors
- 👤 Burton G. Christensen
- 👤 Ronald W. Ratcliffe
- 👤 James V. Heck
- 👤 Thomas N. Salzmann
- 👤 David H. Shih
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 05:33
CPC Classifications
C; C07; C07D; C07D477/00; C07D477/10; C07D477/12; C07D477/14; A; A61; A61P; A61P31/00; A61P31/04; C07F; C07F7/00; C07F7/02; C07F7/08; C07F7/18; C07F7/1804; C07F9/00; C07F9/02; C07F9/547; C07F9/6558; C07F9/65583; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
1146 words
A compound having the formula: ##STR135## wherein: R 1 is hydrogen or methyl; R 4 and R 5 are independently H, CH 3 --, CH 3 CH 2 --, (CH 3 ) 2 CH--, HOCH 2 --, CH 3 CH(OH)--, (CH 3 ) 2 C(OH)--, FCH 2 --, F 2 CH--, F 3 C--, CH 3 CH(F)--, (CH 3 ) 2 C(F)--; CH 3 CF 2 --, or L is a bridging group comprising substituted or unsubstituted C 1 -C 4 straight, C 2 -C 6 branched or C 3 -C 7 cycloalkyl groups wherein the substituents are selected from C 1 -C 6 alkyl, O-C 1 -C 6 alkyl, S-C 1 -C 6 alkyl, CF 3 , N(C 1 -C 6 alkyl) 2 ; ##STR136## is a mono- or bicyclic heteroarylium group containing from 5-11 ring atoms of which up to 5 are heteroatoms in addition to the quaternary nitrogen; wherein: R 2 is (1) an unsubstituted or substituted C 1 -C 6 alkyl radical; (2) an unsubstituted or substituted C 2 -C 6 alkenyl radical; (3) an unsubstituted or substituted C 2 -C 6 alkynyl radical; (4) a C 3 -C 7 cycloalkyl radical in which the ring is substituted or unsubstituted and one or more atoms may be replaced by a heteroatom; (5) a C 3 -C 7 cycloalkyl methyl radical in which the ring may be substituted and one or more atoms may be replaced by a heteroatom; (6) an unsubstituted or substituted C 5 -C 7 cycloalkenyl radical; (7) an unsubstituted or substituted bivalent C 2 -C 6 alkylidene radical, optionally interrupted by a heteroatom, and joined to the heteroarylium group to form a ring which is carbocyclic or in which one or more atoms is replaced by a heteroatom and wherein the new ring may contain one or more double bonds; (8) an unsubstituted or substituted phenyl or heteroaryl radical; (9) an unsubstituted or substituted phenyl (C 1 -C 4 alkyl) or heteroaryl (C 1 -C 4 alkyl) radical; (10) a cyano (C 1 -C 4 alkyl) radical; (11) a carboxy (C 1 -C 4 alkyl) radical; (12) a sulfo (C 1 -C 4 alkyl) radical; (13) a carbamoyl (C 1 -C 4 alkyl) radical; (14) a phosphonyl (C 1 -C 4 alkyl) radical; (15) a hydroxy (C 1 -C 4 alkyl) radical; or (16) an amino (C 1 -C 4 alkyl) radical in which the nitrogen atom is unsubstituted or substituted with one to three C 1 -C 4 alkyl groups; wherein the substituents in the above definitions of R 2 are independently selected from the group consisting of: (a) a trifluoromethyl group; (b) a halogen atom; (c) an unsubstituted or substituted C 1 -C 4 alkoxyl radical; (d) a hydroxy group; (e) an unsubstituted or substituted (C 1 -C 6 alkyl) carbonyloxy radical; (f) a carbamoyloxy radical which is unsubstituted or substituted on nitrogen with one or two C 1 -C 4 alkyl groups; (g) a C 1 -C 6 alkylthio radical, C 1 -C 6 alkylsulfinyl radical or C 1 -C 6 alkylsulfonyl radical, each of which is unsubstituted or substituted on the alkyl group; (h) a sulfo group; (i) a sulfamoyl group which is unsubstituted or substituted on nitrogen by one or two C 1 -C 4 alkyl groups; (j) a formylamino group; (k) an unsubstituted or substituted (C 1 -C 6 alkyl)carbonylamino radical; (l) a (C 1 -C 4 alkoxyl) carbonylamino radical; (m) a ureido group in which the terminal nitrogen is unsubstituted or substituted with one or two C 1 -C 4 alkyl groups; (n) an arylsulfonamido or a (C 1 -C 6 alkyl)sulfonamido group; (o) a cyano group; (p) a formyl or acetalized formyl radical; (q) an unsubstituted or substituted (C 1 -C 6 alkyl)carbonyl radical wherein the carbonyl is free or acetalized; (r) an unsubstituted or substituted phenylcarbonyl or heteroarylcarbonyl radical; (s) a carboxyl group; (t) a (C 1 -C 6 alkoxy)carbonyl radical; (u) a carbamoyl radical which is unsubstituted or substituted on nitrogen by one or two C 1 -C 4 alkyl groups; (v) an N-hydroxycarbamoyl or N(C 1 -C 4 alkoxy)carbamoyl radical in which the nitrogen atom may be additionally substituted by a C 1 -C 4 alkyl group; (w) a thiocarbamoyl group; (x) a 5-(1H)-tetrazolyl group; (y) a phosphonate group --P(O) (OH)OR' where R' is C 1 -C 3 alkyl; (z) an alkyl phosphonate group --(CH 2 ) n P(O) (OH) (OR') where n=1 to 3 and R' is C 1 -C 3 alkyl; (aa) hydrogen; (ab) an unsubstituted or substituted C 1 -C 6 alkyl radical; (ac) an unsubstituted or substituted C 2 -C 6 alkenyl radical; (ad) an unsubstituted or substituted C 2 -C 6 alkynyl radical; (ae) a C 3 -C 7 cycloalkyl radical in which the ring is substituted or unsubstituted and one or more atoms may be replaced by a heteroatom; (af) a C 3 -C 7 cycloalkyl methyl radical in which the ring may be substituted and one or more atoms may be replaced by a heteroatom; (ag) an unsubstituted or substituted C 5 -C 7 cycloalkenyl radical; (ah) an unsubstituted or substituted phenyl or heteroaryl radical; and (ai) an unsubstituted or substituted phenyl (C 1 -C 4 alkyl) or heteroaryl (C 1 -C 4 alkyl) radical; and R 3 is (a) hydrogen; (b) an unsubstituted or substituted C 1 -C 6 alkyl radical; (c) an unsubstituted or substituted C 2 -C 6 alkenyl radical; (d) an unsubstituted or substituted C 2 -C 6 alkynyl radical; (e) a C 3 -C 7 cycloalkyl radical in which the ring is substituted or unsubstituted and one or more atoms may be replaced by a heteroatom; (f) a C 3 -C 7 cycloalkyl methyl radical in which the ring may be substituted and one or more atoms may be replaced by a heteroatom; (g) an unsubstituted or substituted C 5 -C 7 cycloalkenyl radical; (h) an unsubstituted or substituted phenyl or heteroaryl radical; (i) an unsubstituted or substituted phenyl (C 1 -C 4 alkyl) or heteroaryl (C 1 -C 4 alkyl) radical; and (j) a trifluoromethyl group; (k) a halogen atom; (l) an unsubstituted or substituted C 1 -C 4 alkoxyl radical; (m) a C 1 -C 6 alkylthio radical, C 1 -C 6 alkylsulfinyl radical or C 1 -C 6 alkylsulfonyl radical, each of which is unsubstituted or substituted on the alkyl group; (n) a mono (C 1 -C 4 alkyl) amino or di(C 1 -C 4 alkyl)amino group, each of which is unsubstituted or substituted on the alkyl group; or (o) a cyano group; and Y is (i) COOH or a pharmaceutically acceptable ester or salt thereof, (ii) COOR wherein R is a removable carboxy protecting group, (iii) COOM wherein M is an alkali metal, or (iv) COO - ; provided that when Y is other than (iv) a counterion Z - is provided.
Claim 2
Dependent Claim
1146 words
A compound having the formula: ##STR135## wherein: R 1 is hydrogen or methyl; R 4 and R 5 are independently H, CH 3 --, CH 3 CH 2 --, (CH 3 ) 2 CH--, HOCH 2 --, CH 3 CH(OH)--, (CH 3 ) 2 C(OH)--, FCH 2 --, F 2 CH--, F 3 C--, CH 3 CH(F)--, (CH 3 ) 2 C(F)--; CH 3 CF 2 --, or L is a bridging group comprising substituted or unsubstituted C 1 -C 4 straight, C 2 -C 6 branched or C 3 -C 7 cycloalkyl groups wherein the substituents are selected from C 1 -C 6 alkyl, O-C 1 -C 6 alkyl, S-C 1 -C 6 alkyl, CF 3 , N(C 1 -C 6 alkyl) 2 ; ##STR136## is a mono- or bicyclic heteroarylium group containing from 5-11 ring atoms of which up to 5 are heteroatoms in addition to the quaternary nitrogen; wherein: R 2 is (1) an unsubstituted or substituted C 1 -C 6 alkyl radical; (2) an unsubstituted or substituted C 2 -C 6 alkenyl radical; (3) an unsubstituted or substituted C 2 -C 6 alkynyl radical; (4) a C 3 -C 7 cycloalkyl radical in which the ring is substituted or unsubstituted and one or more atoms may be replaced by a heteroatom; (5) a C 3 -C 7 cycloalkyl methyl radical in which the ring may be substituted and one or more atoms may be replaced by a heteroatom; (6) an unsubstituted or substituted C 5 -C 7 cycloalkenyl radical; (7) an unsubstituted or substituted bivalent C 2 -C 6 alkylidene radical, optionally interrupted by a heteroatom, and joined to the heteroarylium group to form a ring which is carbocyclic or in which one or more atoms is replaced by a heteroatom and wherein the new ring may contain one or more double bonds; (8) an unsubstituted or substituted phenyl or heteroaryl radical; (9) an unsubstituted or substituted phenyl (C 1 -C 4 alkyl) or heteroaryl (C 1 -C 4 alkyl) radical; (10) a cyano (C 1 -C 4 alkyl) radical; (11) a carboxy (C 1 -C 4 alkyl) radical; (12) a sulfo (C 1 -C 4 alkyl) radical; (13) a carbamoyl (C 1 -C 4 alkyl) radical; (14) a phosphonyl (C 1 -C 4 alkyl) radical; (15) a hydroxy (C 1 -C 4 alkyl) radical; or (16) an amino (C 1 -C 4 alkyl) radical in which the nitrogen atom is unsubstituted or substituted with one to three C 1 -C 4 alkyl groups; wherein the substituents in the above definitions of R 2 are independently selected from the group consisting of: (a) a trifluoromethyl group; (b) a halogen atom; (c) an unsubstituted or substituted C 1 -C 4 alkoxyl radical; (d) a hydroxy group; (e) an unsubstituted or substituted (C 1 -C 6 alkyl) carbonyloxy radical; (f) a carbamoyloxy radical which is unsubstituted or substituted on nitrogen with one or two C 1 -C 4 alkyl groups; (g) a C 1 -C 6 alkylthio radical, C 1 -C 6 alkylsulfinyl radical or C 1 -C 6 alkylsulfonyl radical, each of which is unsubstituted or substituted on the alkyl group; (h) a sulfo group; (i) a sulfamoyl group which is unsubstituted or substituted on nitrogen by one or two C 1 -C 4 alkyl groups; (j) a formylamino group; (k) an unsubstituted or substituted (C 1 -C 6 alkyl)carbonylamino radical; (l) a (C 1 -C 4 alkoxyl) carbonylamino radical; (m) a ureido group in which the terminal nitrogen is unsubstituted or substituted with one or two C 1 -C 4 alkyl groups; (n) an arylsulfonamido or a (C 1 -C 6 alkyl)sulfonamido group; (o) a cyano group; (p) a formyl or acetalized formyl radical; (q) an unsubstituted or substituted (C 1 -C 6 alkyl)carbonyl radical wherein the carbonyl is free or acetalized; (r) an unsubstituted or substituted phenylcarbonyl or heteroarylcarbonyl radical; (s) a carboxyl group; (t) a (C 1 -C 6 alkoxy)carbonyl radical; (u) a carbamoyl radical which is unsubstituted or substituted on nitrogen by one or two C 1 -C 4 alkyl groups; (v) an N-hydroxycarbamoyl or N(C 1 -C 4 alkoxy)carbamoyl radical in which the nitrogen atom may be additionally substituted by a C 1 -C 4 alkyl group; (w) a thiocarbamoyl group; (x) a 5-(1H)-tetrazolyl group; (y) a phosphonate group --P(O) (OH)OR' where R' is C 1 -C 3 alkyl; (z) an alkyl phosphonate group --(CH 2 ) n P(O) (OH) (OR') where n=1 to 3 and R' is C 1 -C 3 alkyl; (aa) hydrogen; (ab) an unsubstituted or substituted C 1 -C 6 alkyl radical; (ac) an unsubstituted or substituted C 2 -C 6 alkenyl radical; (ad) an unsubstituted or substituted C 2 -C 6 alkynyl radical; (ae) a C 3 -C 7 cycloalkyl radical in which the ring is substituted or unsubstituted and one or more atoms may be replaced by a heteroatom; (af) a C 3 -C 7 cycloalkyl methyl radical in which the ring may be substituted and one or more atoms may be replaced by a heteroatom; (ag) an unsubstituted or substituted C 5 -C 7 cycloalkenyl radical; (ah) an unsubstituted or substituted phenyl or heteroaryl radical; and (ai) an unsubstituted or substituted phenyl (C 1 -C 4 alkyl) or heteroaryl (C 1 -C 4 alkyl) radical; and R 3 is (a) hydrogen; (b) an unsubstituted or substituted C 1 -C 6 alkyl radical; (c) an unsubstituted or substituted C 2 -C 6 alkenyl radical; (d) an unsubstituted or substituted C 2 -C 6 alkynyl radical; (e) a C 3 -C 7 cycloalkyl radical in which the ring is substituted or unsubstituted and one or more atoms may be replaced by a heteroatom; (f) a C 3 -C 7 cycloalkyl methyl radical in which the ring may be substituted and one or more atoms may be replaced by a heteroatom; (g) an unsubstituted or substituted C 5 -C 7 cycloalkenyl radical; (h) an unsubstituted or substituted phenyl or heteroaryl radical; (i) an unsubstituted or substituted phenyl (C 1 -C 4 alkyl) or heteroaryl (C 1 -C 4 alkyl) radical; and (j) a trifluoromethyl group; (k) a halogen atom; (l) an unsubstituted or substituted C 1 -C 4 alkoxyl radical; (m) a C 1 -C 6 alkylthio radical, C 1 -C 6 alkylsulfinyl radical or C 1 -C 6 alkylsulfonyl radical, each of which is unsubstituted or substituted on the alkyl group; (n) a mono (C 1 -C 4 alkyl) amino or di(C 1 -C 4 alkyl)amino group, each of which is unsubstituted or substituted on the alkyl group; or (o) a cyano group; and Y is (i) COOH or a pharmaceutically acceptable ester or salt thereof, (ii) COOR wherein R is a removable carboxy protecting group, (iii) COOM wherein M is an alkali metal, or (iv) COO - ; provided that when Y is other than (iv) a counterion Z - is provided.
Claim 3
Dependent Claim
12 words
A compound of claim 1 wherein R 1 is CH 3 .
Claim 4
Dependent Claim
19 words
A compound of claim 1 wherein L is substituted or unsubstituted branched or linear C 1 -C 4 alkyl.
Claim 5
Dependent Claim
25 words
A compound of claim 3 wherein L is --CH 2 --, --CH(CH 3 )--, --(CH 2 ) 2 --, or --CH(CH 3 )CH 2 --.
Claim 6
Dependent Claim
14 words
A compound of claim 1 wherein ##STR137## is monocyclic heteroarylium having 5-6 ring atoms.
Claim 7
Dependent Claim
16 words
A compound of claim 5 wherein ##STR138## is a pyridinium, diazolium, triazolium, thiazolium or oxazolium group.
Claim 8
Dependent Claim
50 words
A compound of claim 1 wherein R 2 is an unsubstituted or substituted C 1 -C 6 alkyl group, carboxy (C 1 -C 4 alkyl), carbamoyl (C 1 -C 4 alkyl), sulfo (C 1 -C 4 alkyl), heteroaryl (C 1 -C 4 alkyl), or cyano (C 1 -C 4 alkyl).
Claim 9
Dependent Claim
32 words
A compound of claim 1 wherein R 3 is hydrogen, N(C 1 -C 3 alkyl), O-C 1 -C 4 alkyl, C 1 -C 4 alkyl, CN, CF 3 or CH 2 OH.
Claim 10
Dependent Claim
26 words
A compound of claim 1 wherein the compound is a member selected from the group wherein R 1 is H and ##STR139## is selected from ##STR140##
Claim 11
Dependent Claim
27 words
A compound of claim 1 wherein the compound is a member selected from the group wherein R 1 is CH 3 and ##STR141## is selected from ##STR142##
Claim 12
Dependent Claim
10 words
A compound of claim 1 having the stereochemical configuration: ##STR143##
Claim 13
Dependent Claim
9 words
The compound of claim 11 having the structure: ##STR144##
Claim 14
Dependent Claim
16 words
A compound of claim 11 wherein R 1 is CH 3 , having a beta configuration.
Claim 15
Dependent Claim
12 words
The combination of a compound of claim 1 and a DHP inhibitor.
Claim 16
Dependent Claim
12 words
A combination of claim 14 wherein the DHP inhibitor is 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid.
Claim 17
Dependent Claim
23 words
A pharmaceutical composition for antibiotic use comprising an antibacterially effective amount of a compound of claim 1 and, optionally, a pharmaceutically acceptable carrier.
Claim 18
Dependent Claim
31 words
A pharmaceutical composition for antibiotic use comprising an antibacterially effective amount of a compound of claim 1, an inhibitorily effective amount of a DHP inhibitor, and, optionally, a pharmaceutically acceptable carrier.
Claim 19
Dependent Claim
14 words
A pharmaceutical composition according to claim 17 wherein the DHP inhibitor is 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid.
Claim 20
Dependent Claim
39 words
A method of treating bacterial infections in human or animal subjects in need of such treatment comprising coadministering to said subjects an antibacterially effective amount of a compound of claim 1, an inhibitorily effective amount of a DHP inhibitor.
Claim 21
Dependent Claim
13 words
A method according to claim 19 wherein the DHP inhibitor is 7-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid.
Claim 22
Dependent Claim
31 words
A method of treating bacterial infections in human or animal subjects in need of such treatment comprising administering to said subjects an antibacterially effective amount of a compound of claim 1.
References Cited (Backward Citations)
US4348320A
Cited
US4189493A
Cited
US4218459A
Cited
US4260627A
Cited
US4465632A
Cited
JPS5660852A
Cited
US4312871A
Cited
US4262011A
Cited
US4262009A
Cited
US4347355A
Cited
US4377591A
Cited
US4341706A
Cited
GB2092147A
Cited
JPS57145086A
Cited
JPS57145087A
Cited
GB2119371A
Cited
GB2122196A
Cited
US4536335A
Cited
GB2128187A
Cited
US4680292A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-03-08 | 1991-09-07 | 1992-03-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-03-08 | 1995-09-07 | 1996-03-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-03-08 | 1999-09-07 | 2000-03-08 | $7700.00 | Window Closed / Lapsed |